Oppenheimer analyst Jay Olson lowered the firm’s price target on Immuneering (IMRX) to $21 from $25 and keeps an Outperform rating on the shares. The firm notes the company reported Q1 financial results, including $15.5M total OpEx and $35.9M cash, which should support operations into 2026. Most important, Immuneering reiterated near-term updates of IMM-1-104 from the ongoing Phase 2a trial in 1L PDAC, suggesting the update will include PFS data from over 30 patients.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
- Positive Outlook for Immuneering: Buy Rating Backed by Strategic Developments and Promising Clinical Data
- Immuneering Corp. Reports Promising Q1 2025 Results
- Immuneering reports Q1 EPS (42c), consensus (58c)
- Immuneering’s Promising Potential: Buy Rating Backed by Strategic Expansion and Data Generation
- Immuneering Corp. Reports Promising Cancer Trial Results